A phase 2 study looked at recurrent/metastatic platinum refractory HNSCC patients naive to anti-EGFR therapy who were given Cetuximab alone vs. Cetuximab with Alpelisib. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.